LMO4 promotes OSCC progression by inducing RAB17 degradation and ferroptosis resistance
8.0
来源：
Nature
关键字：
mRNA
发布时间：
2025-11-11 03:48
摘要：
LMO4 is identified as a critical oncogenic factor in oral squamous cell carcinoma (OSCC), promoting tumor growth and metastasis by inducing RAB17 degradation and enhancing ferroptosis resistance. The study reveals that high LMO4 levels correlate with poor patient prognosis, suggesting its potential as a therapeutic target. Mechanistically, LMO4 regulates RAB17 through ubiquitin-mediated degradation, impacting cellular proliferation and migration. Targeting the LMO4-RAB17 axis may offer new strategies for treating aggressive OSCC.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0
business_impact
0.5分+0.5
scientific_rigor
1.5分+1.5
timeliness_innovation
1.5分+1.5
investment_perspective
2.5分+2.5
market_value_relevance
1.0分+1.0
team_institution_background
0.5分+0.5
technical_barrier_competition
0.5分+0.5
关键证据
LMO4 expression was markedly higher in OSCC tissues and was associated with poorer overall survival.
Restoration of RAB17 expression reduced malignant behaviors in OSCC.
LMO4 promotes OSCC progression through post-translational regulation of RAB17.
真实性检查
否
AI评分总结
LMO4 is identified as a critical oncogenic factor in oral squamous cell carcinoma (OSCC), promoting tumor growth and metastasis by inducing RAB17 degradation and enhancing ferroptosis resistance. The study reveals that high LMO4 levels correlate with poor patient prognosis, suggesting its potential as a therapeutic target. Mechanistically, LMO4 regulates RAB17 through ubiquitin-mediated degradation, impacting cellular proliferation and migration. Targeting the LMO4-RAB17 axis may offer new strategies for treating aggressive OSCC.